China Sky One Medical Provides Sales Forecast for 13 New Products
Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a leading
fully integrated pharmaceutical company in
(“PRC”), today provided an update on the commercialization plan for the 13 new
products. Based on additional market research and customer feedback, the
Company estimates aggregate incremental 2010 sales of approximately
from these products.
In March and April, the Company successfully launched the following three
products as planned: Oxymetazoline Hydrochloride Nasal Drops for acute and
chronic rhinitis, sinusitis and allergic rhinitis; Moschus Liniment for relief
of pain from scathe, wound, rheumatism and arthrosis; Ftibamzone Liniment to
treating herpes and fungal skin infection.
The remaining ten new products will be launched during the rest of 2010.
Product Name Description Expected Launch
Tobramycin Eye To treat acute infection on eyelids May 2010
Drops
Calcium Folinate An auxiliary therapy for sprue (a May 2010
Injection disease of the small intestine),
malnutrition, pregnancy- or infancy-
related megaloblastic anemia, and
colonic and rectal cancer
Sodium To treat allergic conjunctivitis May 2010
Cromoglicate
Eye Drops
Aciclovir Gel To treat the skin infection due to June 2010
varicella-zoster virus and the herpes
simplex virus
Antiasthma cream To treat cough, asthma and chronic June 2010
bronchitis
Naphazoline For the sterilization and rheum June 2010
Hydrochloride prevention and for the treatment
Chlorpheniramine of rheumatic diseases
Maleate and
Benzalkonium
Bromide Spray
Skincare Cream To treat skin diseases such as acne, July 2010
bottle nose, chromophytosis
and vitiligo
Nasal Drop To treat the snuffle August 2010
Propylgallate To treat cerebro-vascular infarction, August 2010
for Injection angina, hypertention and coronary
heart diseases
Dithranol to treat different types of September 2010
ointment psoriasis, such as plaque psoriasis,
guttate psoriasis and hypertrophy
psoriasis;
“We look forward to the commercial launch of the remaining ten new
products in 2010. China Sky One remains committed to the research and
development of new products to create more growth opportunities in the
long-term,” said Mr.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
(“TDR”), Harbin First Bio-Engineering Company Limited (“First”), Heilongjiang
Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang
Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major revenue
source. For more information, visithttp://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as “believe,” “expect,” “may,” “will,”
“should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include the production timeline and its effect on the
Company’s operational results. Actual results could differ materially from the
expectations reflected in such forward-looking statements as a result of a
variety of factors, including the risks associated with the ability to launch
new products, market acceptance of new product launches, achievability of
management’s estimates of product sales, the effect of changing economic
conditions in
development, risks associated with rapid technological change, and the
potential of introduced or undetected flaws and defects in products, and other
risk factors detailed in reports filed with the Securities and Exchange
Commission from time to time.
For further information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-0451-8703-2617
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Ms. Mabel Zhang, Vice President
Tel: +1-310-954-1353
Email: mabel.zhang@ccgir.com
SOURCE China Sky One Medical, Inc.